TWD 59.1
(-3.27%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | 674.97 Million TWD | 77.23% |
2022 | 380.84 Million TWD | -65.43% |
2021 | 1.1 Billion TWD | 162.05% |
2020 | 420.41 Million TWD | 19123.35% |
2019 | -2.21 Million TWD | -103.86% |
2018 | 57.23 Million TWD | -84.87% |
2017 | 378.19 Million TWD | -42.99% |
2016 | 663.42 Million TWD | 103.77% |
2015 | 325.57 Million TWD | 18.85% |
2014 | 273.94 Million TWD | 465.04% |
2013 | -75.04 Million TWD | -302.94% |
2012 | 36.97 Million TWD | -84.84% |
2011 | 243.92 Million TWD | -24.08% |
2010 | 321.29 Million TWD | 0.0% |
2009 | - TWD | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q1 | 187.72 Million TWD | -20.21% |
2024 Q2 | 166.27 Million TWD | -11.43% |
2023 FY | 674.97 Million TWD | 77.23% |
2023 Q4 | 235.28 Million TWD | 366.21% |
2023 Q3 | -88.38 Million TWD | -189.14% |
2023 Q2 | 99.15 Million TWD | 327.74% |
2023 Q1 | -43.53 Million TWD | -112.6% |
2022 Q3 | 501.49 Million TWD | 1499.72% |
2022 Q1 | -430.44 Million TWD | -190.14% |
2022 FY | 380.84 Million TWD | -65.43% |
2022 Q4 | 345.62 Million TWD | -31.08% |
2022 Q2 | -35.82 Million TWD | 91.68% |
2021 Q3 | -51.81 Million TWD | 27.67% |
2021 Q2 | -71.64 Million TWD | -2.08% |
2021 FY | 1.1 Billion TWD | 162.05% |
2021 Q1 | -70.18 Million TWD | -165.16% |
2021 Q4 | -148.35 Million TWD | -186.32% |
2020 Q2 | -42.89 Million TWD | -61.78% |
2020 Q3 | 20.44 Million TWD | 147.66% |
2020 FY | 420.41 Million TWD | 19123.35% |
2020 Q1 | -26.51 Million TWD | -151.39% |
2020 Q4 | 107.7 Million TWD | 426.83% |
2019 Q2 | -21.99 Million TWD | 77.05% |
2019 Q1 | -95.84 Million TWD | -341.37% |
2019 Q4 | 51.59 Million TWD | -48.4% |
2019 Q3 | 99.97 Million TWD | 554.45% |
2019 FY | -2.21 Million TWD | -103.86% |
2018 Q1 | -1.18 Million TWD | -102.26% |
2018 Q3 | 3.34 Million TWD | -78.25% |
2018 Q4 | 39.7 Million TWD | 1087.77% |
2018 FY | 57.23 Million TWD | -84.87% |
2018 Q2 | 15.36 Million TWD | 1393.6% |
2017 Q3 | 57.36 Million TWD | -61.03% |
2017 Q2 | 147.19 Million TWD | 21.63% |
2017 Q1 | 121.01 Million TWD | -19.69% |
2017 FY | 378.19 Million TWD | -42.99% |
2017 Q4 | 52.62 Million TWD | -8.25% |
2016 Q2 | 191.72 Million TWD | 23.03% |
2016 FY | 663.42 Million TWD | 103.77% |
2016 Q3 | 165.17 Million TWD | -13.84% |
2016 Q1 | 155.83 Million TWD | 19.37% |
2016 Q4 | 150.68 Million TWD | -8.77% |
2015 Q4 | 130.55 Million TWD | 54.99% |
2015 Q2 | 41.72 Million TWD | -39.59% |
2015 Q1 | 69.06 Million TWD | 92.91% |
2015 Q3 | 84.22 Million TWD | 101.86% |
2015 FY | 325.57 Million TWD | 18.85% |
2014 Q1 | 48.64 Million TWD | -0.18% |
2014 FY | 273.94 Million TWD | 465.04% |
2014 Q4 | 35.8 Million TWD | -63.11% |
2014 Q3 | 97.04 Million TWD | 4.97% |
2014 Q2 | 92.44 Million TWD | 90.04% |
2013 Q4 | 48.73 Million TWD | -3.51% |
2013 Q1 | -180.48 Million TWD | -681.9% |
2013 Q2 | 6.2 Million TWD | 103.44% |
2013 FY | -75.04 Million TWD | -302.94% |
2013 Q3 | 50.5 Million TWD | 714.6% |
2012 Q2 | 27.09 Million TWD | -25.4% |
2012 Q1 | 36.31 Million TWD | -33.61% |
2012 Q3 | -3.66 Million TWD | -113.53% |
2012 Q4 | -23.08 Million TWD | -529.82% |
2012 FY | 36.97 Million TWD | -84.84% |
2011 Q1 | 79.34 Million TWD | -75.3% |
2011 Q4 | 54.7 Million TWD | -2.18% |
2011 Q2 | 53.95 Million TWD | -32.0% |
2011 Q3 | 55.91 Million TWD | 3.64% |
2011 FY | 243.92 Million TWD | -24.08% |
2010 Q4 | 321.29 Million TWD | 0.0% |
2010 Q1 | - TWD | 0.0% |
2010 Q2 | - TWD | 0.0% |
2010 FY | 321.29 Million TWD | 0.0% |
2010 Q3 | - TWD | 0.0% |
2009 FY | - TWD | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Grape King Bio Ltd | 2.49 Billion TWD | 72.965% |
Standard Chem & Pharm CO., LTD. | 1.25 Billion TWD | 46.412% |
Maywufa Company Ltd. | 211.01 Million TWD | -219.865% |
ScinoPharm Taiwan, Ltd. | 314.49 Million TWD | -114.625% |
Lotus Pharmaceutical Co., Ltd. | 4.9 Billion TWD | 86.233% |
LIWANLI Innovation Co., Ltd. | - TWD | -Infinity% |
YungShin Global Holding Corporation | 929.61 Million TWD | 27.392% |
PhytoHealth Corporation | -121.67 Million TWD | 654.727% |
SCI Pharmtech, Inc. | 160.3 Million TWD | -321.07% |
PharmaEssentia Corporation | - TWD | -Infinity% |
Bora Pharmaceuticals Co., LTD. | 5.24 Billion TWD | 87.141% |